Embracing Future Lt (8YY.SI) traded down -11.11 % during a 24 hours period ending at 12:31 AM Central Europe on Tuesday 27th. One Embracing Future Lt stock can currently be bought for about SGD 0.03 on popular exchanges. Current supply of Embracing Future Lt stocks is 1.7 bn. Embracing Future Lt has a current market capitalization of SGD 41.6 mn and approximately SGD 48.7 k worth of Embracing Future Lt was traded on exchanges in the last 24 hours. Since last month end, Embracing Future Lt has traded -33.33 % down. Simple moving average of last 200 days is at SGD 0.05. The highest price of past 52 weeks was recorded at SGD 0.09 on 01/20/2026. 52 weeks low was at SGD 0.02 on 11/19/2025.

Here is how related stocks have performed in the past 24 hours:

  • Sunright (S71.SI) traded up 2.63 % and now trades at SGD 0.39. Sunright has a market capitalisation of SGD 47.9 mn. Current price/earnings ratio for Sunright is 36.

  • Euda Health (EUDA) traded down -4.41 % and now trades at USD 14.46. Euda Health has a market capitalisation of USD 38.3 mn.

  • Fu Yu (F13.SI) traded flat 0 % and now trades at SGD 0.06. Fu Yu has a market capitalisation of SGD 48.8 mn. Current price/earnings ratio for Fu Yu is 23.03.

  • Wong Fong Industries (1A1.SI) traded down -1.5 % and now trades at SGD 0.2. Current market capitalisation for Wong Fong Industries is SGD 46.3 mn. Current price/earnings ratio for Wong Fong Industries is 4.22.

  • Vallianz (WPC.SI) traded flat 0 % and now trades at SGD 0.04. Vallianz has a market capitalisation of SGD 48.5 mn. Vallianz has a current price to earnings ratio of 5.11.

About Embracing Future Lt

Biolidics Ltd. is a medical technology company that specializes in developing cell enrichment systems for cancer diagnosis, prognosis, and treatment selection and monitoring applications. The company is actively involved in the fields of biotechnology, life and medical science, and electronics related industrial design services. Biolidics offers a range of products and services, including the ClearCell FX1 System, a automated in vitro diagnostic medical device that separates and enriches cancer cells from blood; CTChip, a single-use microfluidic biochip that enriches circulating tumor cells; and various consumables such as red blood cell lysis buffer, resuspension buffer, and cleansing solutions. The company has a strategic collaboration with Sysmex Corporation for the development of laboratory assays in the field of circulating tumor cells. Biolidics Ltd. serves academic and research institutes, hospitals, and laboratories in Singapore, Japan, China, Europe, the United States, Hong Kong, Australia, Taiwan, and Korea. The company was founded in 2009 and has its main headquarters in Singapore. The company’s website is www.biolidics.com , and it is listed on the Singapore Exchange.